This script search US Code. View Rule
Menu Item - Home
Menu Item - Agenda Main page
Menu Item - Historical Agenda
Menu Item - Historical Agenda
Menu Item - Agenda Search
Menu Item - EO Dashboard
Menu Item - Reg Review
Menu Item - EO Agency lists
Menu Item - EO Search
Menu Item - EO Historical Reports
Menu Item - Review Counts
Menu Item - OIRA Letters
Menu Item - EOM 12866 Search
Menu Item - EO XML Reports
Menu Item - ICR Dashboard page
Menu Item - ICR Main page
Menu Item - ICR Search
Menu Item - ICR XML Reports
Menu Item - FAQ
Menu Item - Additional Resources
Menu Item - Contact Us
Search: Agenda Reg Review ICR
       Search

View Rule

View EO 12866 Meetings Printer-Friendly Version     Download RIN Data in XML

HHS/FDA RIN: 0910-AC52 Publication ID: Fall 2005 
Title: Submission of Standardized Electronic Study Data From Clinical Studies Evaluating Human Drugs and Biologics 
Abstract: The Food and Drug Administration is proposing to amend the regulations governing the format in which clinical study data (CSD) are required to be submitted for new drug applications (NDAs), biological license applications (BLAs), and abbreviated new drug applications (ANDAs). The proposal would revise our regulations to require that CSD submitted for NDAs, BLAs, and ANDAs, and their supplements and amendments be provided in an electronic format that FDA can process, review, and archive. The proposal would also require the use of standardized data structure, terminology, and code sets to allow for more efficient and comprehensive review of CSD. 
Agency: Department of Health and Human Services(HHS)  Priority: Other Significant 
RIN Status: Previously published in the Unified Agenda Agenda Stage of Rulemaking: Proposed Rule Stage 
Major: Undetermined  Unfunded Mandates: No 
CFR Citation: 21 CFR 314.50; 21 CFR 601.12; 21 CFR 314.94 
Legal Authority: 21 USC 355; 21 USC 371; 42 USC 262 
Legal Deadline:  None

Statement of Need: Before a drug is approved for marketing, FDA must determine that the drug is safe and effective for its intended use. This determination is based in part on clinical study data (CSD) that are submitted as part of the marketing application. At present, FDA accepts CSD in paper and electronic formats. When CSD are submitted to FDA only on paper, the information must be transcribed by hand into electronic form for review and analysis. This process is extremely time consuming and is prone to data entry error. CSD submitted to FDA in electronic format have generally been more efficient to process and review. FDAs proposed rule would require the submission of CSD in a standardized electronic format. The standardized CSD format would improve patient safety and enhance health care delivery by enabling FDA to process, review, and archive CSD more efficiently. Standardization of CSD would also enhance the ability to share study data and communicate results. Investigators and industry would benefit from the use of standards throughout the lifecycle of a study--in data collection, reporting, and analysis. The proposal would work in concert with ongoing agency and national initiatives to support increased use of electronic technology as a means to improve patient safety and enhance health care delivery.

Summary of the Legal Basis: Our legal authority to amend our regulations governing the submission and format of CSD for human drugs and biologics derives from sections 505 and 701 of the act (U.S.C. 355 and 371) and section 351 of the Public Health Service Act (42 U.S.C. 262).

Alternatives: FDA considered issuing a guidance document outlining the electronic submission and the standardization of CSD, but not requiring electronic submission of CSD in the standardized format. This alternative was rejected because the agency would not fully benefit from standardization until it became the industry standard, which could take up to 20 years. We also considered a number of different implementation scenarios, from shorter to longer time-periods. The two-year time-period was selected because the agency believes it would provide ample time for applicants to comply without too long a delay in the effective date. A longer time-period would delay the benefit from the increased efficiencies, such as standardization of review tools across applications, and the incremental cost saving to industry would be small.

Anticipated Costs and Benefits: FDA estimates that the costs to industry resulting from the proposal would include some one-time costs and some potential annual recurring costs. One-time costs would include, among other things, the cost of converting CSD to standard structures, terminology, and cost sets (i.e., purchase of software to convert CSD); the cost of submitting electronic CSD (i.e., purchase of file transfer programs); and the cost of installing and validating the software and training personnel. Additional annual recurring costs may result from software purchases and licensing agreements for use of proprietary terminologies. The proposal could result in many long-term benefits for industry and for the agency, including improved patient safety through more efficient, comprehensive, and accurate data review; enhanced communication among sponsors, clinicians, and FDA through improved access to and sharing of CSD; and reduced data management costs through the standardization of data formats.

Risks: None.

Timetable:
Action Date FR Cite
NPRM  06/00/2006   
Regulatory Flexibility Analysis Required: Yes  Government Levels Affected: None 
Small Entities Affected: Businesses  Federalism: No 
Included in the Regulatory Plan: Yes 
Agency Contact:
Martha Nguyen
Senior Regulatory Counsel
Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research, WO 51, Room 6250, 10903 New Hampshire Avenue,
Silver Spring, MD 20993-0002
Phone:301 796-3601
Fax:301 847-8440
Email: martha.nguyen@fda.hhs.gov

 
About Us   Vertical Spacer Spacer Related Resources   Vertical Spacer Spacer Disclosure   Vertical Spacer Spacer Accessibility   Vertical Spacer Spacer Privacy Policy   Vertical Spacer Spacer Contact Us